Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics
GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage..
United States National Library of Medicine
News and Video Search Results
News coverage
-
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
GlobeNewswire
-
World Human Gene Sequencing Markets, Strategies & Trends Report 2021-2025: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
GlobeNewswire
-
Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
GlobeNewswire
-
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
GlobeNewswire
0 shares
1 views
You might like
United States National Library of Medicine media coverage
Hollywall Entertainment Inc. Signs Agreement to Acquire Omnipoint Technology Group
GlobeNewswire
WASHINGTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – Hollywall Entertainment, Inc. (OTC: HWAL), advances its..
-
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
GlobeNewswire
-
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
GlobeNewswire
-
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
GlobeNewswire
-
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
GlobeNewswire
Advertisement
More coverage
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
GlobeNewswire
· Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx^® at Week 12 vs. placebo,..
-
Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
GlobeNewswire
-
Global Chronic Wound Care Market to Hit USD 16.36 Billion with 6.2% CAGR by 2027; Presence of Several Large Scale Healthcare Companies will Bode well for Market Growth, says Fortune Business Insights™
GlobeNewswire
-
Outlook on the Worldwide LEDs Used in Test/Measurement, Medical & Other Science Devices Industry to 2029
GlobeNewswire
-
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
GlobeNewswire